• Connect With Us
Clinical Research

Active In-House Studies at Virginia Hospital Center

Investigator: Walter L. Atiga, M.D.

Mentor Protocol Title: ENSURE Cardiac Resynchronization Therapy Study.

Investigator: Walter L. Atiga, M.D.

Guidant Protocol Title: REFLEX Study: ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance.

Investigator: John R. Garrett, M.D.

Protocol Number: Nabi Biopharmaceuticals Protocol Nabi-1366.
Protocol Title: A multicenter, randomized, placebo-controlled, double-blinded study to evaluate safety and immunogenicity of StaphVAX, a bivalent staphylococcus aureus glycoconjugate vaccine in adult patients undergoing cardiovascular surgery.

Investigator: John R. Garrett, M.D.

Protocol Number: Alexion and Proctor & Gamble Protocol 2003141
Protocol Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of 2 mg/kg bolus plus 24-hour 0.5 mg/kg/hr infusion pexelizumab in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass.

Investigator: Ramanath Gopalan, M.D. 

Protocol Number: Eli Lilly Protocol F1D-US-HGLS.
Protocol Title: Olanzipineversus Aripiprazole in the treatment of acutely ill patients with schizophrenia.

Investigator: Michael P. Notarianni, M.D.

Protocol Number: AstraZeneca Protocol 4522US/0001
Protocol Title: A 12-week, randomized, open-label, 3-arm, parallel group, multicenter, phase IIIb study comparing the efficacy and safety of Rosuvastatin 20mg and 40mg with that of Atorvastatin 80mg in subjects with acute coronary syndromes [LUNAR].

Investigator: Talal A. Munasifi, M.D.

Protocol Number: WIRB 96564
Protocol Title: Adjunct study for Mentor H/S silicone gel-filled mammary prosthesis.

Investigator: Dr. Tariq Shahab, M.D.

Protocol Number: WIRB 1585
Protocol Title: Safety and efficacy of Jomed Jostent coronary stent-graft in the treatment of free perforations during percutaneous coronary interventions.

Investigator:  Ramanath Gopalan, M.D.

Protocol Number:   Pfizer A1281110
Protocol Title:   A Four-Week Double-Blind Multi-Center Study Comparing the Efficacy and Safety of Ziprasidone to Aripiprazole in Subjects with Scizophrenia or Schizoaffective Disorder Needing Inpatient Care

Investigator:  Steven K. Neufeld, M.D.

Protocol Number:  1
Protocol Title:  The Foot and Ankle Post-op Pain Trial (the FA-POP trial):  A Patient Oriented Study

Investigator:  Ramanath Gopalan, M.D.

Protocol Number:  Pfizer and Organon A7501005
Protocol Title:  A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual Azenapine vs. Olanzapine and Placebo in In-Patients with an Acute Manic Episode.

Investigator:  Ramanath Gopalan, M.D.

Protocol Number: Pfizer and Organon A7501006
Protocol Title:  A Double-Blind, 9-Week Extension Study Evaluating the Safety and Maintenance of Effect of Azenapine vs. Olanzapine in the Treatment of Subjects with Acute Mania.

Investigator:  Ramanath Gopalan, M.D.

Protocol Number:  Solvay S1543004
Protocol Title: A Randomized, Double-Blind, Olanzapine-Referenced, Parallel-Group Safety and Efficacy Study of Flexible Doses of Bifeprunox in the Long-Term Treatment of Schizophrenia (Extension of Protocol S1543003)

Investigator:  Rita Wong, EdD., PT

Protocol Title:  Barriers and Facilitators to the Diffusion of a Comprehensive Balance and Falls Prevention Program within a Hospital.

Investigator:Ramanath Gopalan, M.D.

Protocol Number: Pfizer and Organon 041023
Protocol Title:AMulticenter, Randomized, Double-Blind, Fixed -Dose, 6-Week Trial of Efficacy and Safety of Asenapine Compared with Placebo Using Haloperidol Positive Control in Subjects with an Acute Exacerbation of Schizophrenia

Investigator:Ramanath Gopalan, M.D.

Number: Pfizer and Organon 04513
Protocol Title: A Multicenter, Double-Blind, Flexible-Dose, Long-Term Extension Trial 6-Week Trial of the Safety and Maintenance of Effect of Asenapine Using Haloperidol Positive Control in Subjects  Who Complete Protocol 041023

Investigator:  Walter Atiga

Title:  Medtronic Partners HF
Multi-Site Program to Access and Review Trending Information and Evaluate CoR Relation to Symptoms in Patients with Heart Failure

Investigator:  Charanjit S. Khurana, M.D.

Number:  Pfizer A7641006
Title: A Phase 2 Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ET-00216 in Patients with Acute Coronary Syndromes

Investigator:  David Duhamel, M.D.

Number Asthmatx 04-02
Protocol Title: Safety and Effectiveness of the Alair System for the Treatment of Asthma:  A Muticenter Randomized Clinical Trial (Asthma Intervention Research (AIR2) Trial)

Investigator:  Ramanath Gopalan, M.D.

Number: GlaxoSmithKline NAA104606
Protocol Title: A Multicenter, Double-Blind, Double Dummy, Placebo-Controlled, Randomized, Adaptive, Dose-Range Study to Evaluate the Safety and Efficacy of SB-773812 Administered Once daily for 12 Weeks in Adults with Schizophrenia"

Share:
Find a Doctor
Search
Contact Info

If you wish to inquire about specific trials, clinical research processes (that is, the approval process and trial monitoring processes), and guidelines for clinical research at Virginia Hospital Center, please contact
Deborah Tominack, RN

1701 N. George Mason Drive | Arlington, VA 22205-3698 | tel 703.558.5000
© 2016 Virginia Hospital Center All rights reserved